Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo.

Navailles S, Di Giovanni G, De Deurwaerdère P.

CNS Neurosci Ther. 2015 Sep;21(9):745-7. doi: 10.1111/cns.12436. Epub 2015 Jul 24. No abstract available.

PMID:
26205756
2.

Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Navailles S, Bioulac B, Gross C, De Deurwaerdère P.

Neurobiol Dis. 2010 Apr;38(1):136-43. doi: 10.1016/j.nbd.2010.01.012. Epub 2010 Jan 22.

PMID:
20096781
3.

In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.

Sarre S, Lanza M, Makovec F, Artusi R, Caselli G, Michotte Y.

Eur J Pharmacol. 2008 Apr 28;584(2-3):297-305. doi: 10.1016/j.ejphar.2008.02.027. Epub 2008 Feb 19.

PMID:
18342306
4.

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.

El Arfani A, Bentea E, Aourz N, Ampe B, De Deurwaerdère P, Van Eeckhaut A, Massie A, Sarre S, Smolders I, Michotte Y.

Neuropharmacology. 2014 Oct;85:198-205. doi: 10.1016/j.neuropharm.2014.05.024. Epub 2014 May 24.

PMID:
24863042
5.
6.

L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.

Kääriäinen TM, García-Horsman JA, Piltonen M, Männistö PT.

Neuroreport. 2009 Feb 18;20(3):313-8. doi: 10.1097/WNR.0b013e328321e704.

PMID:
19188858
8.

Endogenous morphine-like compound immunoreactivity increases in parkinsonism.

Charron G, Doudnikoff E, Laux A, Berthet A, Porras G, Canron MH, Barroso-Chinea P, Li Q, Qin C, Nosten-Bertrand M, Giros B, Delalande F, Van Dorsselaer A, Vital A, Goumon Y, Bezard E.

Brain. 2011 Aug;134(Pt 8):2321-38. doi: 10.1093/brain/awr166. Epub 2011 Jul 8.

PMID:
21742735
9.

The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations.

Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, McDowell LL, Vanase-Frawley MA, Fisher KE, Rubitski DM, Stutzman-Engwall KJ, Nelson RT, Horner WE, Gorczyca RR, Hajos M, Siok CJ.

J Pharmacol Exp Ther. 2012 Jun;341(3):681-91. doi: 10.1124/jpet.112.192351. Epub 2012 Mar 9.

PMID:
22408061
10.

The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.

Rose S, Ramsay Croft N, Jenner P.

Brain Res. 2007 Feb 16;1133(1):110-4. Epub 2006 Dec 29.

PMID:
17196564
11.

MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.

Jonkers N, Sarre S, Ebinger G, Michotte Y.

Brain Res. 2002 Feb 1;926(1-2):149-55.

PMID:
11814417
12.

Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.

Lindgren HS, Ohlin KE, Cenci MA.

Neuropsychopharmacology. 2009 Nov;34(12):2477-88. doi: 10.1038/npp.2009.74. Epub 2009 Jul 15.

13.

Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants.

Krobert KA, Brattelid T, Levy FO, Kaumann AJ.

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371(6):473-9. Epub 2005 Jul 13.

PMID:
16012870
14.

MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.

Jonkers N, Sarre S, Ebinger G, Michotte Y.

Eur J Pharmacol. 2000 Nov 3;407(3):281-91.

PMID:
11068024
15.

Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.

Chai W, Chan KY, de Vries R, van den Bogeardt AJ, de Maeyer JH, Schuurkes JA, Villalón CM, Saxena PR, Danser AH, MaassenVanDenBrink A.

Life Sci. 2012 Apr 9;90(13-14):538-44. doi: 10.1016/j.lfs.2012.01.009. Epub 2012 Feb 1.

PMID:
22326501
16.

Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.

Gołembiowska K, Dziubina A.

Neurotox Res. 2012 Feb;21(2):222-30. doi: 10.1007/s12640-011-9263-x. Epub 2011 Aug 10.

17.

Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats.

Navailles S, Milan L, Khalki H, Di Giovanni G, Lagière M, De Deurwaerdère P.

CNS Neurosci Ther. 2014 Jul;20(7):671-8. doi: 10.1111/cns.12275. Epub 2014 Apr 28.

PMID:
24775184
18.

L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.

Espadas I, Darmopil S, Vergaño-Vera E, Ortiz O, Oliva I, Vicario-Abejón C, Martín ED, Moratalla R.

Neurobiol Dis. 2012 Dec;48(3):271-81. doi: 10.1016/j.nbd.2012.07.012. Epub 2012 Jul 20.

PMID:
22820144
19.

l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.

Pendolino V, Bagetta V, Ghiglieri V, Sgobio C, Morelli E, Poggini S, Branchi I, Latagliata EC, Pascucci T, Puglisi-Allegra S, Calabresi P, Picconi B.

Exp Neurol. 2014 Nov;261:377-85. doi: 10.1016/j.expneurol.2014.07.006. Epub 2014 Jul 21.

PMID:
25058044
20.

Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.

Westin JE, Andersson M, Lundblad M, Cenci MA.

Eur J Neurosci. 2001 Oct;14(7):1171-6.

PMID:
11683909

Supplemental Content

Support Center